Plus   Neg

Progenics Pharmaceuticals Inc. (PGNX) Is Sinking On Phase 3 Study Results

Progenics Pharmaceuticals Inc. (PGNX) announced after the bell Wednesday that the co-primary endpoint of sensitivity of its Phase 3 study of 1404, its prostate specific membrane antigen, was not met.

Progenics Pharmaceuticals has gapped open sharply lower Thursday morning and is now down 1.22 at $6.07 on above average volume. The stock has tumbled to a 6 1/2 month low.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT